The core activity of ReMedys is to develop and promote innovative therapeutic approaches for patients with severe diseases without effective treatment, regardless of their commercial potential. To this end, ReMedys works in partnership with academic research institutions and industry experts to translate research results into clinical trials and develops new medicines in a project-based approach.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Research and development programs for translational therapy development, with project-dedicated teams, partnering between academic research and industry, and transition to clinical proof-of-concept.
Healthspan Research Program (KHARIS)
Program to develop new strategies for healthy ageing, using systems biology and genetics approaches, personalised healthspan metrics, data integration, target identification, and digital health twins.
Neurodegeneration Program ALS
Program to develop new treatment approaches for ALS, including gene therapy against mutant SOD1, preclinical evaluation, and preparation for human use.
Systems Genetics Platform
Systems genetics data platform with mouse and human data, genotype-phenotype linking, QTL mapping, GWAS, PheWAS, mediation analysis, and clinical translation.
Comparisons
ReMedys Foundation in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank ReMedys Foundation by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once ReMedys Foundation has claimed this profile, we'll publish editorial articles and case studies here together.